Halaven grows for Eisai but R&D costs hit group profits
This article was originally published in Scrip
Global sales of Eisai's novel cancer drug Halaven (eribulin) may have risen by 27% in the fiscal first quarter ended 30 June, but at a modest JPY7.0bn ($71 million), the product still has a long way to go to reach its intended blockbuster status.
You may also be interested in...
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.